HEPA - Hepion Pharmaceuticals, Inc.

Insider Purchase by Stetz Gary S. (Interim CEO)

1 Month
After Trade
Before Trade

Loading data...

Trade Summary

1 week ago, Stetz Gary S., serving as Interim CEO at Hepion Pharmaceuticals, Inc. (HEPA), purchased 1,250,000 shares at $0.04 per share, for a total transaction value of $50,000.00. Following this transaction, Stetz Gary S. now holds 1,250,000 shares of HEPA.

The trade was executed on Tuesday, April 21, 2026 and publicly disclosed via SEC Form 4 filing on Monday, April 27, 2026, 6 days after the trade was made.

Hepion Pharmaceuticals, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider buying activity in this sector can provide valuable signals about industry trends and company-specific developments.

Stetz Gary S.

Interim CEO

Gary S. Stetz is an experienced corporate executive serving as Interim Chief Executive Officer of Hepion Pharmaceuticals, Inc. (HEPA), a position he assumed following the resignation of Dr. Kaouthar Lbiati on April 13, 2026.[[1]](https://www.stocktitan.net/sec-filings/HEPA/8-k-hepion-pharmaceuticals-inc-reports-material-event-4a53d6494346.html)[[3]](https://www.tradingview.com/news/tradingview:61a343f5da6c9:0-hepion-pharmaceuticals-appoints-gary-stetz-as-interim-ceo-kaouthar-lbiati-resigns/)[[4]](https://www.americanpharmaceuticalreview.com/1315-News/624664-Hepion-CEO-Steps-Down-Board-Installs-Interim-Leader-and-Reshapes-Governance/) Prior to this role, Stetz was an existing board member of the company, and the board appointed him to lead during the leadership transition while seeking a permanent CEO.[[4]](https://www.americanpharmaceuticalreview.com/1315-News/624664-Hepion-CEO-Steps-Down-Board-Installs-Interim-Leader-and-Reshapes-Governance/) He recently purchased 1,250,000 shares of HEPA stock for an estimated $50,000, signaling confidence in the company's direction.[[2]](https://www.quiverquant.com/news/Hepion+Pharmaceuticals+Stock+(HEPA)+Opinions+on+Executive+Separation+and+ctRNA+Licensing) Stetz holds additional director roles at New Found Life, Inc. and Canton Strategic, reflecting his broader involvement in corporate governance.[[6]](https://www.marketscreener.com/insider/GARY-STETZ-A028KS/) Detailed information on his prior career highlights and education is not available in current sources.

View full insider profile →

Trade Price

$0.04

Quantity

1,250,000

Total Value

$50,000.00

Shares Owned

1,250,000

Trade Date

Tuesday, April 21, 2026

7 days ago

SEC Filing Date

Monday, April 27, 2026

Filed 6 days after trade

HEALTHCAREBIOTECHNOLOGY

Discussion

Sign in to join the discussion.
Loading comments…
View news mentioning HEPA

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/5982156

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime